Статья

COVID-19: Analysis of Drug Repositioning Practice

P. Savosina, D. Druzhilovskii, V. Poroikov,
2021

An outbreak of a new coronavirus disease (COVID-19) in China in December 2019 became the epicenter for the spread of a global pandemic. The SARS-CoV-2 coronavirus causes a cascade of respiratory diseases similar to severe acute respiratory syndrome (SARS). Currently, there is no effective, specific, and safe treatment for COVID-19 to suppress the virus in the human body. The present study searched for pharmacological substances with antiviral activity for possible drug repositioning based on experimental and theoretical information in a series of publications on in vitro assays of agents against SARS-CoV-2. An analysis identified 46 well-known pharmaceutical substances that could be used for drug repositioning to create a therapy for COVID-19. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • P. Savosina
    V. N. Orekhovich Institute of Biomedical Chemistry, 10/7 Pogodinskaya St., Moscow, 119121, Russian Federation
  • D. Druzhilovskii
  • V. Poroikov
Название журнала
  • Pharmaceutical Chemistry Journal
Том
  • 54
Выпуск
  • 10
Страницы
  • 989-996
Ключевые слова
  • almitrine; amodiaquine; anisomycin; anti-SARS-CoV-2 agent; asenapine; auranofin; bazedoxifene; camostat; candesartan; cetylpyridinium salt; chloroquine; ciclesonide; clemastine; clofazimine; cyclosporine; digitoxin; digoxin; dronedarone; favipiravir; fendiline; fluphenazine; gemcitabine; hexachlorophene; homoharringtonine; hydroxychloroquine; ivermectin; loperamide; mefloquine; methylene blue; monensin; mycophenolic acid; nafamstat; niclosamide; nitazoxanide; ouabain; oxyclozanide; penciclovir; raloxifene; rapamycin; regorafenib; remdesivir; ribavirin; salinomycin; sorafenib; tamoxifen; thioridazine; tilorone; toremifene; trifluoperazine; umifenovir; vortioxetine; antiviral activity; Article; controlled study; coronavirus disease 2019; drug repositioning; EC50; experimental study; human; IC50; in vitro study; inhibition kinetics; nonhuman; quantitative assay; Severe acute respiratory syndrome coronavirus 2; theoretical study
Издатель
  • Springer
Тип документа
  • journal article
Источник
  • scopus